A Phase 1 Dose-Escalation Study of Intravenous MST-997 Formulated in Intralipid 20% Administered Weekly in Subjects With Advanced Malignant Solid Tumors

Trial Profile

A Phase 1 Dose-Escalation Study of Intravenous MST-997 Formulated in Intralipid 20% Administered Weekly in Subjects With Advanced Malignant Solid Tumors

Discontinued
Phase of Trial: Phase I

Latest Information Update: 11 Nov 2008

At a glance

  • Drugs Simotaxel (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Wyeth; Wyeth Pharmaceuticals
  • Most Recent Events

    • 11 Nov 2008 Checked against NYU Medical Center site.
    • 09 Dec 2006 Status change
    • 17 Aug 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top